Live Breaking News & Updates on Research At Seagen

Intravesical enfortumab vedotin demonstrated antitumor activity and limited systemic exposure in preclinical models of non-muscle invasive bladder cancer Antibody specificity, antitumor activity and safety profile of SGN-ALPV in preclinical models provide basis for the first-in-human phase 1 clinical study BOT. ....

United States , David Caouette , Peggy Pinkston , Scott Peterson , Enfortumab Vedotin , Astellas Pharma Us Inc , Research At Seagen , Seagen Inc , Exchange Commission , Astellas Pharma Inc , American Association For Cancer Research , European Union , Corporate Communications , American Association , Cancer Research , Annual Meeting , New Orleans , Astellas Pharma , Senior Vice President , Seagen Programs Presented , Seagen Presentations , Clinical Pharmacology , Immune Mechanisms Invoked , Drug Conjugates , Annual Report , Vedotin Antibody Drug Conjugate Targeting ,